Gene test mix-up brings scrutiny to industry
By Alejandro Martínez-Cabrera,
San Francisco Chronicle
| 06. 11. 2010
[Quotes CGS's Jesse Reynolds]
Last week, retired marketing specialist Nora Probasco called her brother with a half-serious, half-joking question: Was she adopted?
The issue came up after the 59-year-old genealogy hobbyist from Louisville, Ky., received the results of a test she took through 23andMe, a Google-backed firm that allows people to learn more about their ancestry and some medical conditions through DNA analysis.
"I was shocked," she said. "What it came down to, the way I know to read them, is that my mom is not my mom."
To her relief, it turned out to be a mistake. Last Friday, the Mountain View firm acknowledged in a post on its Web site that it mixed up the samples of 96 clients and sent them the wrong ones. The company corrected the mistake relatively quickly, but observers see the potential for similar errors that could lead individuals to make ill-informed decisions regarding their health.
The company, which was founded in 2006, said in an e-mail that the mistake occurred when a tray with 96 samples was misplaced. The company added that new procedures have been... see more
Related Articles
By Gina Kolata, The New York Times | 01.17.2023
Photo by ANIRUDH on Unsplash
Terry Jackson lives a life dominated by sickle cell disease. The genetic disorder, in which misshapen red cells become wedged in blood vessels, causes him daily bone pain and lower back pain and has sent...
By David Jensen, The California Stem Cell Report | 01.11.2023
Two prestigious campuses of the University of California are eyeing the creation of an entity that would cover the multimillion-dollar price tags of genetic therapies for the life-threatening bubble baby disease.
Also likely to be involved in some fashion is the California...
By Liz Essley Whyte, The Wall Street Journal | 01.10.2023
The Food and Drug Administration is pressing pause on drug-company testing of experimental medicines more often, a side effect of the industry’s move into promising but less-proven technologies.
The agency, which must sign off before companies can begin testing an...
By Emily Sohn, Nature | 01.09.2023
Each day, around 350 people in the United States die from lung cancer. Many of those deaths could be prevented by screening with low-dose computed tomography (CT) scans. But scanning millions of people would produce millions of images, and there...
